IMMUNITYBIO, INC. Increase Decrease In Operating Lease Liability
IMMUNITYBIO, INC. (IBRX) reported Increase Decrease In Operating Lease Liability of $4.00 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2025-11-05
- IMMUNITYBIO, INC. increase decrease in operating lease liability for the quarter ending 2025-06-30 was $4.00M.
- IMMUNITYBIO, INC. increase decrease in operating lease liability for the quarter ending 2024-12-31 was -$1.54M.
- IMMUNITYBIO, INC. increase decrease in operating lease liability for the quarter ending 2024-09-30 was -$1.52M.
- IMMUNITYBIO, INC. increase decrease in operating lease liability for the quarter ending 2024-06-30 was -$1.52M, a 901.05% decline year-over-year.
- IMMUNITYBIO, INC. increase decrease in operating lease liability for fiscal 2024 was -$5.47M.
- IMMUNITYBIO, INC. increase decrease in operating lease liability for fiscal 2023 was -$2.98M.
- IMMUNITYBIO, INC. increase decrease in operating lease liability for fiscal 2022 was -$4.32M.
- IMMUNITYBIO, INC. increase decrease in operating lease liability for fiscal 2021 was -$4.16M.
| Period end | Increase Decrease In Operating Lease Liability | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2025-06-30 | $4.00M 10-Q · filed 2025-11-05 | $4.00M 10-Q · filed 2025-08-05 | |||
| 2024-12-31 | -$1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$3.05M derived: sum of 2 quarters · filed 2025-03-03 | -$4.58M derived: sum of 3 quarters · filed 2025-03-03 | -$5.47M 10-K · filed 2025-03-03 | |
| 2024-09-30 | -$1.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$3.04M derived: sum of 2 quarters · filed 2024-11-12 | -$3.94M 10-Q · filed 2024-11-12 | -$4.49M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2024-06-30 | -$1.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$2.42M 10-Q · filed 2024-08-12 | -$2.97M derived: sum of 3 quarters · filed 2025-03-03 | -$4.08M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2024-03-31 | -$898.00K 10-Q · filed 2024-05-09 | -$1.45M derived: sum of 2 quarters · filed 2025-03-03 | -$2.56M derived: sum of 3 quarters · filed 2025-03-03 | -$2.37M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-12-31 | -$549.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$1.66M derived: sum of 2 quarters · filed 2025-03-03 | -$1.47M derived: sum of 3 quarters · filed 2025-03-03 | -$2.98M 10-K · filed 2025-03-03 | |
| 2023-09-30 | -$1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$918.00K derived: sum of 2 quarters · filed 2024-11-12 | -$2.43M 10-Q · filed 2024-11-12 | -$4.44M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | $190.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$1.32M 10-Q · filed 2024-08-12 | -$3.33M derived: sum of 3 quarters · filed 2025-03-03 | -$3.45M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | -$1.51M 10-Q · filed 2024-05-09 | -$3.52M derived: sum of 2 quarters · filed 2025-03-03 | -$3.64M derived: sum of 3 quarters · filed 2025-03-03 | -$5.49M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2022-12-31 | -$2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$2.13M derived: sum of 2 quarters · filed 2025-03-03 | -$3.98M derived: sum of 3 quarters · filed 2025-03-03 | -$4.32M 10-K · filed 2025-03-03 | |
| 2022-09-30 | -$112.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$1.97M derived: sum of 2 quarters · filed 2023-11-09 | -$2.31M 10-Q · filed 2023-11-09 | -$2.82M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-06-30 | -$1.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$2.19M 10-Q · filed 2023-08-08 | -$2.71M derived: sum of 3 quarters · filed 2024-03-19 | -$3.38M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-03-31 | -$339.00K 10-Q · filed 2023-05-11 | -$856.00K derived: sum of 2 quarters · filed 2024-03-19 | -$1.53M derived: sum of 3 quarters · filed 2024-03-19 | -$3.03M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2021-12-31 | -$517.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$1.19M derived: sum of 2 quarters · filed 2024-03-19 | -$2.69M derived: sum of 3 quarters · filed 2024-03-19 | -$4.16M 10-K · filed 2024-03-19 | |
| 2021-09-30 | -$670.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$2.17M derived: sum of 2 quarters · filed 2022-11-09 | -$3.65M 10-Q · filed 2022-11-09 | -$6.16M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | -$1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$2.98M 10-Q · filed 2022-08-08 | -$5.49M derived: sum of 3 quarters · filed 2023-03-01 | ||
| 2021-03-31 | -$1.47M 10-Q · filed 2022-05-10 | -$3.99M derived: sum of 2 quarters · filed 2023-03-01 | |||
| 2020-12-31 | -$2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$5.61M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | -$3.09M 10-Q · filed 2021-11-12 | ||||
| 2019-12-31 | -$4.48M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |